NCT07493109 2026-03-25
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
The First Hospital of Jilin University
Phase 3 Recruiting
Clinical Trials
20 trialsNCT07253220 2025-11-28
TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma
Sun Yat-sen University
Phase NA Not yet recruiting
NCT06966232 2025-05-11
Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers
Sun Yat-sen University
Phase 3 Recruiting
NCT04294498 2025-03-26
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
National Taiwan University Hospital
Phase 2 Active not recruiting
NCT02650271 2024-01-23
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
Guangxi Medical University
Phase 3 Completed
NCT04539119 2020-09-04
Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA
Ruijin Hospital
Phase 3 Unknown
NCT04392700 2020-05-19
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection
Sun Yat-sen University
Phase 3 Unknown
NCT04160897 2019-11-13
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
Ruijin Hospital
Unknown
NCT02777814 2019-01-22
Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers
Sun Yat-sen University
Phase 2 Unknown
NCT03680183 2018-09-28
Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Unknown
NCT02777801 2017-10-13
Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers
Sun Yat-sen University
Phase 2 Unknown
NCT01580202 2017-06-29
Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine
Seoul National University Hospital
Phase 3 Completed
NCT01765231 2017-01-10
Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma
Peking University
Phase 4 Unknown
NCT01768195 2017-01-10
Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
Peking University
Phase 4 Unknown
NCT00931229 2016-11-09
Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients
National Health Research Institutes, Taiwan
Phase NA Unknown
NCT00824707 2016-04-01
Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-related Primary Liver Cancer
Eastern Hepatobiliary Surgery Hospital
Phase NA Completed
NCT01914744 2013-08-02
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
Fudan University
Phase 2 Unknown
NCT01894269 2013-07-23
Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
Sun Yat-sen University
Phase 4 Unknown
NCT00555334 2009-04-01
LAM-RFA
Sun Yat-sen University
Phase 4 Unknown
NCT00768157 2009-02-09
Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma
Sun Yat-sen University
Phase 4 Unknown